SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff, which traders link to the Democrats midterm gains and fears that political pushback could slow AI and data-center expansion, has put SPY in focus as tech and semiconductor shares unwind. The community is divided between calling the decline an overreaction and buying the dip versus expecting further downside amid volatility and selling pressure.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

NLST is under pressure amid a broad selloff in technology and memory stocks, with traders debating whether concerns about AI/data-center investment and policy risks or company-specific factors are driving the decline. Many are treating the pullback as a buying opportunity ahead of the Q3 report, while watching for an SK Hynix agreement and developments in Netlists Kingston litigation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigels quarterly results and early VEPPANU launch are driving discussion: traders are encouraged by the drugs initial uptake and record product sales, but some focus on the earnings miss, weaker margins, and cash burn. The stocks sharp decline has sharpened the debate over whether VEPPANUs growth potential outweighs the disappointing headline results.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is under pressure as traders question whether Big Techs heavy AI and data-center spending will generate returns quickly enough to offset its effect on free cash flow. The community is split between fears of a deeper tech correction and views that the selloff is a rotation or pullback creating a buying opportunity.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XE is drawing attention amid a sharp selloff, with traders citing broader weakness in nuclear stocks and concerns about post-IPO share supply and bearish analyst coverage. Some are buying the dip on the strength of Amazon-backed reactor projects and federal support, while others worry that commercialization and meaningful revenue remain years away.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings disappointing Q3 results and lowered full-year outlook triggered a sharp selloff, with traders criticizing rising costs and managements heavy investment in its Predictions business. The main debate is whether that investment can build a growth engine or instead leaves DraftKings vulnerable to competition from Kalshi and Polymarket and delays profitability.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzles Q3 results beat expectations and management raised its FY2026 outlook while issuing a positive initial FY2027 forecast, fueling a sharp rally. Bulls point to continued growth and profitability, while some traders warn that valuation and a slower projected growth pace could weigh on the stock; short-squeeze talk is speculative.

Teradyne, Inc.. The Group's principal activity is to design, manufacture, sell and service automatic test equipment for electronic companies. It operates in two segments: Semiconductor Test Systems and System Test Group. Semiconductor Test Systems segment designs, manufactures, sells and supports Semiconductor Test products and services on a world wide basis. Systems Test Group segment is comprised of 3 business units: Mil/Aero, Commercial Board Test and Diagnostic Solutions. It also operates in the Semiconductor Test; Military/Aerospace test, Commercial Circuit Board test and Automotive Diagnostics test. On 14-Nov-2008, it acquired Eagle Test Systems Inc, On 24-Jan-2008, it acquired Nextest Systems Corporation ('Nextest').

Teradyne, Inc.

Teradynes sharp selloff despite a strong quarterly beat is driving discussion, with traders pointing to cautious near-term guidance, margin pressure and valuation concerns. Some see the drop as a buying opportunity, while others question whether AI-related chip-testing demand can sustain the stocks prior gains.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is under pressure amid a broad crypto and tech selloff, with traders linking its decline to weakness in Bitcoin and Ethereum. Many complain that the stock is falling harder than ETH and criticize Tom Lees stewardship, while others see the discount to asset value and share buybacks as reasons to buy the dip.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is caught in a sharp semiconductor selloff as traders worry that post-midterm calls for tighter data-center rules could slow AI infrastructure spending and chip demand. The community is split between seeing the drop as an overreaction and buying opportunity, and expecting more downside if AI-capex growth or data-center expansion slows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should Know

Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates

Stevanato (STVN) delivered earnings and revenue surprises of +5.88% and +3.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD

Equity

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs. 


OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.  


This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising ratings and price targets.read more...

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. 

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock closed down 22% on Monday and continued to drop on Wednesday and Thursday.&nbsp;</li><li>The current popular treatment for Wet AMD is Regeneron’s Eylea.&nbsp;</li><li>Ocular still plans to file for approval of AXPAXLI in the fourth quarter of 2026.&nbsp;</li></ul>Shares of Ocular Therapeutix Inc (<a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a>) fell 5% on Thursday and are on track for their worst week since April 2024, after two rivals posted positive updates in the crowded market for longer-lasting eye injections.The stock closed down 21% on Monday and continued to drop on Wednesday and Thursday after a brief 3% recovery on Tuesday, as competitors posted positive clinical updates that weighed on optimism around Ocular’s lead drug, AXPAXLI, aimed at treating Wet age-related macular degeneration. &nbsp;<h2 class="st-heading-2">KOD, FDMT Raise The Durability Bar</h2>Wet AMD is a form of vision loss driven by leaky blood vessels under the retina. The standard drug, Regeneron’s Eylea, works, but patients need repeated injections into the eye. The race is on to see how long a dose can last.Kodiak Sciences said earlier this week that its late-stage DAYBREAK study met its main goals. Two experimental drugs, Zenkuda and tabirafusp-ted, matched Eylea on vision after one year in patients who had not been treated before. Researchers measured vision as the change in how many letters a patient could read. Kodiak also said 54% of Zenkuda patients were on a six-month schedule at one year, under strict rules that called for a new shot if any fluid showed up on a scan. The company reported no cases of inflammation inside the eye with Zenkuda and a cataract rate of 0.5%, versus 0.9% with Eylea. It plans to file Zenkuda with the FDA in the fourth quarter. Kodiak shares more than doubled on the update on Monday and are up 160% so far this week.4D Molecular Therapeutics, meanwhile, said the first patients had entered 4SIGHT, a late-stage trial of its one-time gene therapy, 4D-150, in diabetic macular edema, a related disease. Updated two-year data from an earlier study showed lasting gains in vision and retinal swelling, and fewer extra shots than standard Eylea dosing, the company said. 4D-150 is already in late-stage testing for wet AMD.<h2 class="st-heading-2">Ocular’s Own Path Is Unchanged</h2>Ocular’s lead drug, AXPAXLI, is a dissolving implant that slowly releases axitinib inside the eye, aiming for months of control from a single shot. A late-stage study met its main goal in February, and a mid-September meeting with the FDA was described as positive. The company still plans to file in the fourth quarter of 2026, with a possible launch in 2027.RBC Capital Markets analyst Lisa Walter called Monday’s drop overdone, arguing the valuation does not reflect a drug that could reach about $1 billion in sales a few years after launch, and said Ocular still has the best-positioned long-acting treatment, according to a report from Investing.com.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock stayed in ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘extremely high.’A Stocktwits user said that the company must be valued at about $6 billion. <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> is currently valued at about $1.6 billion<stembedurl>https://stocktwits.com/Kylea1/message/665562045</stembedurl>Another user opined that the selloff might increase the chances of a buyout, given the company is a “steal” at its current valuation compared with Kodiak’s market valuation of $6.19 billion.<stembedurl>https://stocktwits.com/dhowe888/message/665561130</stembedurl><a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock has dropped 40% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nktr-stock-eyes-worst-day-in-over-3-years-on-rezpeg-data-william-blair-still-sees-a-durability-edge/cZD0hlzRB0g">NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ocular Therapeutix logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs. 

Kodiak Sciences Inc

Ocular Therapeutix Inc

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$11.25
Prev Close	$12.28
Open	$12.11
Dividend Yield	0.00%
50-Day Moving Average	$13.40
Beta	1.53
Avg. Volume	1.02M
PE Ratio	-4.13

52-Week High	$16.93
52-Week Low	$6.96
Market Capitalization	$678.4M
EPS (Annual)	-$2.42
Price to Book	1.52
Revenue Per Employee	$434,739.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

FDMT Fundamentals